**5.2 Study**

The dosing regimens for danaparoid (provided in all but one case series and a single case report), dalteparin and UDCA in adults and children in the remaining reports are shown in **Table 8**. For danaparoid the adult regimen 2500 U/day follows that approved for DIC treatment in Japan and is close to the lower limit of the recommended dosing range for thrombosis treatment. This has been adapted for use in children and the 60–70 U/Kg/day is similar to that used for paediatric (V)TE treatment [116]. However this is equivalent to 4200–4900 U/day for a 70 kg adult, twice the dosing intensity received by adults for SOS/TA-TMA prevention.
